Stockreport

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates

Zura Bio Limited - Class A Ordinary shares  (ZURA) 
PDF Continued advancement of two Phase 2 clinical trials evaluating tibulizumab in hidradenitis suppurativa (HS) (TibuSHIELD) and systemic sclerosis (SSc) (TibuSURE), with t [Read more]